GET DAILY SIGNALSAXON vs VCYT: Weighing Recurring Revenue Strength After Recent Setbacks
Key Takeaways
- AXON grew revenue 28% and software revenue 43% in its latest quarter, but cut its annual outlook after roughly $130 million in federal counter-drone deployments slipped into 2027.
- VCYT beat quarterly earnings estimates, yet its core Decipher Prostate franchise decelerated and management moderated its 2027 revenue growth outlook.
- Both stocks have pulled back sharply in recent weeks, making relative trend stability and recurring revenue quality the key differentiators in this stock comparison.
- Tickeron AI Verdict: AXON is the favored ticker, supported by a stronger recurring software revenue engine, a large contracted backlog, and more consistent long-term growth drivers despite near-term timing headwinds.
- For deeper context, explore AXON Major News and AXON Today's Price Move, as well as VCYT Major News and VCYT Today's Price Move.
- To see which stocks AI-powered systems are favoring right now, visit Trending AI Robots.
Why These Two Stocks Matter for Growth Investors
Axon Enterprise (AXON) and Veracyte (VCYT) operate in unrelated industries — public safety technology versus genomic diagnostics — yet both are high-growth names that reward investors for understanding recurring revenue quality and execution consistency. This stock comparison is relevant for growth-oriented investors and traders weighing a hardware-to-software recurring model against a diagnostics platform built on test volumes. Both companies reported mixed results in recent weeks, and both shares have experienced notable volatility. Comparing their relative performance, market positioning, and trend quality helps clarify which stock currently presents the more consistent setup. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their industries.
Axon Enterprise’s Recent Results
Axon Enterprise develops conducted energy weapons (TASERs), body cameras, and a growing suite of cloud-based software for law enforcement and public safety. The company has built a recurring software business on top of its hardware installed base, including digital evidence management, AI-assisted reporting, and real-time operations tools.
In its most recent quarterly report, AXON grew total revenue 28% to a record level, with software and services revenue up 43% and annual recurring revenue (ARR) rising 40%. Net revenue retention stood near 126%, and future contracted bookings climbed to roughly $15.8 billion. However, the quarter also brought a guidance reduction: three federal counter-drone (Dedrone) deployments worth about $130 million were delayed, lowering the full-year growth outlook to roughly 30% from a prior 32%–34% range. Management attributed the miss to procurement timing rather than lost demand. The shares sold off sharply in response, extending a challenging 2026 in which the stock has traded well below prior highs. Separately, Axon announced a $1.2 billion investment raising its stake in drone maker Skydio, positioning drones as a core platform.
Veracyte’s Latest Quarter
Veracyte is a genomic diagnostics company whose tests include Afirma (thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer), and Decipher Bladder (bladder cancer). Its business model centers on growing test volumes and expanding clinical guideline support across its franchises.
In its latest quarter, VCYT posted adjusted earnings per share (EPS) and revenue above consensus, with revenue reaching roughly $152 million. Afirma thyroid testing remained strong, with double-digit volume and revenue growth, and the company raised its full-year Afirma outlook. At the same time, Decipher Prostate volumes grew about 12% — below management's expectations — prompting a modest narrowing of the 2026 revenue guidance range and a more cautious 2027 outlook of roughly 10% test-volume growth but mid-single-digit revenue growth. The company continues to invest in newer offerings such as Prosigna and its TrueMRD platform. Recent weeks have seen a meaningful decline in the share price and at least one notable analyst downgrade, reflecting reduced visibility into near-term growth.
Head-to-Head Comparison
The two companies diverge sharply on business model and growth architecture. AXON operates a hardware-to-software flywheel: devices such as TASERs and body cameras generate an installed base that fuels high-margin, recurring software subscriptions. Its growth drivers include premium software adoption, AI features, and counter-drone expansion, though hardware margins face pressure from memory costs and federal contract timing. VCYT relies on test utilization and reimbursement, with growth tied to clinical evidence and guideline inclusion across its cancer-testing franchises.
On recent momentum, both names have weakened, but the character of the weakness differs. Axon's setback stems from a timing-related guidance cut even as its highest-margin, recurring segment accelerates. Veracyte's moderation reflects a genuine deceleration in its largest franchise and a more restrained forward outlook. Risk profiles also differ: Axon carries net debt after funding its Skydio investment and faces execution risk in drones, while Veracyte holds a net cash position but contends with reimbursement, competitive, and geopolitical exposure tied to its Israel operations. In terms of market positioning, Axon is a far larger, more diversified recurring-revenue business, whereas Veracyte offers a smaller, specialized diagnostics profile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recurring revenue quality, and relative positioning, Tickeron's AI would currently lean toward AXON. Despite its recent guidance cut, Axon retains accelerating software and services growth, roughly 40% ARR expansion, high net revenue retention, and a large contracted backlog — attributes that tend to support longer-term trend stability. Veracyte's core franchise deceleration and moderated 2027 outlook introduce greater uncertainty into its near-term growth trajectory. This verdict is probabilistic rather than definitive: Axon's path depends on resolving federal deployment timing and defending hardware margins, while Veracyte retains catalysts in new product launches that could re-accelerate growth. Neither outcome is guaranteed. From what I see, this distinction in revenue quality is worth monitoring closely.
Using AI Tools for Market Context
In my own analysis, I frequently review Tickeron’s Trending AI Robots to understand how automated strategies are positioned across sectors like public safety and diagnostics. This resource highlights bots with strong recent performance records, offering a data-driven lens on current market dynamics without replacing individual research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AXON's RSI Indicator slumps oversold zone
The RSI Indicator for AXON moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 55 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 32 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement